Cargando…
A multicentre phase II randomised trial of weekly docetaxel/gemcitabine followed by erlotinib on progression, vs the reverse sequence, in elderly patients with advanced non small-cell lung cancer selected with a comprehensive geriatric assessment (the GFPC 0504 study)
BACKGROUND: Elderly cancer patients form a heterogeneous population in which therapeutic decision-making is often difficult. The aim of this randomised phase II trial was to evaluate the feasibility and activity of weekly docetaxel/gemcitabine (DG) followed by erlotinib after progression (arm A) vs...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3208485/ https://www.ncbi.nlm.nih.gov/pubmed/21934690 http://dx.doi.org/10.1038/bjc.2011.331 |
_version_ | 1782215617973059584 |
---|---|
author | LeCaer, H Barlesi, F Corre, R Jullian, H Bota, S Falchero, L Vergnenegre, A Dujon, C Delhoume, J Y Chouaid, C |
author_facet | LeCaer, H Barlesi, F Corre, R Jullian, H Bota, S Falchero, L Vergnenegre, A Dujon, C Delhoume, J Y Chouaid, C |
author_sort | LeCaer, H |
collection | PubMed |
description | BACKGROUND: Elderly cancer patients form a heterogeneous population in which therapeutic decision-making is often difficult. The aim of this randomised phase II trial was to evaluate the feasibility and activity of weekly docetaxel/gemcitabine (DG) followed by erlotinib after progression (arm A) vs erlotinib followed by DG after progression (arm B) in fit elderly patients with advanced non small-cell lung cancer (NSCLC). METHODS: Elderly chemotherapy-naive patients with stage IIIB/IV NSCLC were selected after a comprehensive geriatric assessment (socioeconomic, cognitive, depression, ADL and IADL assessments). The primary endpoint was the time to second progression (TTP2). Overall survival (OS), the time to first progression (TTP1) and safety were secondary endpoints. RESULTS: Between July 2006 and November 2008, 22 centres enrolled 100 patients. TTP2 was 7.5 and 5.8 months in arm A and arm B, respectively; TTP1 was 4.7 and 2.7 months; and the median OS time was 9.4 and 7.1 months; the respective 1-year survival rates were 36.2 and 31.4%. There was no major unexpected toxicity. CONCLUSION: These results suggest that weekly DG, followed by erlotinib, is a promising treatment for fit elderly patients with NSCLC; the efficacy of the reverse sequence was insufficient to recommend it for EGFR-non-selected patients. |
format | Online Article Text |
id | pubmed-3208485 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-32084852012-10-11 A multicentre phase II randomised trial of weekly docetaxel/gemcitabine followed by erlotinib on progression, vs the reverse sequence, in elderly patients with advanced non small-cell lung cancer selected with a comprehensive geriatric assessment (the GFPC 0504 study) LeCaer, H Barlesi, F Corre, R Jullian, H Bota, S Falchero, L Vergnenegre, A Dujon, C Delhoume, J Y Chouaid, C Br J Cancer Clinical Study BACKGROUND: Elderly cancer patients form a heterogeneous population in which therapeutic decision-making is often difficult. The aim of this randomised phase II trial was to evaluate the feasibility and activity of weekly docetaxel/gemcitabine (DG) followed by erlotinib after progression (arm A) vs erlotinib followed by DG after progression (arm B) in fit elderly patients with advanced non small-cell lung cancer (NSCLC). METHODS: Elderly chemotherapy-naive patients with stage IIIB/IV NSCLC were selected after a comprehensive geriatric assessment (socioeconomic, cognitive, depression, ADL and IADL assessments). The primary endpoint was the time to second progression (TTP2). Overall survival (OS), the time to first progression (TTP1) and safety were secondary endpoints. RESULTS: Between July 2006 and November 2008, 22 centres enrolled 100 patients. TTP2 was 7.5 and 5.8 months in arm A and arm B, respectively; TTP1 was 4.7 and 2.7 months; and the median OS time was 9.4 and 7.1 months; the respective 1-year survival rates were 36.2 and 31.4%. There was no major unexpected toxicity. CONCLUSION: These results suggest that weekly DG, followed by erlotinib, is a promising treatment for fit elderly patients with NSCLC; the efficacy of the reverse sequence was insufficient to recommend it for EGFR-non-selected patients. Nature Publishing Group 2011-10-11 2011-09-20 /pmc/articles/PMC3208485/ /pubmed/21934690 http://dx.doi.org/10.1038/bjc.2011.331 Text en Copyright © 2011 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Clinical Study LeCaer, H Barlesi, F Corre, R Jullian, H Bota, S Falchero, L Vergnenegre, A Dujon, C Delhoume, J Y Chouaid, C A multicentre phase II randomised trial of weekly docetaxel/gemcitabine followed by erlotinib on progression, vs the reverse sequence, in elderly patients with advanced non small-cell lung cancer selected with a comprehensive geriatric assessment (the GFPC 0504 study) |
title | A multicentre phase II randomised trial of weekly docetaxel/gemcitabine followed by erlotinib on progression, vs the reverse sequence, in elderly patients with advanced non small-cell lung cancer selected with a comprehensive geriatric assessment (the GFPC 0504 study) |
title_full | A multicentre phase II randomised trial of weekly docetaxel/gemcitabine followed by erlotinib on progression, vs the reverse sequence, in elderly patients with advanced non small-cell lung cancer selected with a comprehensive geriatric assessment (the GFPC 0504 study) |
title_fullStr | A multicentre phase II randomised trial of weekly docetaxel/gemcitabine followed by erlotinib on progression, vs the reverse sequence, in elderly patients with advanced non small-cell lung cancer selected with a comprehensive geriatric assessment (the GFPC 0504 study) |
title_full_unstemmed | A multicentre phase II randomised trial of weekly docetaxel/gemcitabine followed by erlotinib on progression, vs the reverse sequence, in elderly patients with advanced non small-cell lung cancer selected with a comprehensive geriatric assessment (the GFPC 0504 study) |
title_short | A multicentre phase II randomised trial of weekly docetaxel/gemcitabine followed by erlotinib on progression, vs the reverse sequence, in elderly patients with advanced non small-cell lung cancer selected with a comprehensive geriatric assessment (the GFPC 0504 study) |
title_sort | multicentre phase ii randomised trial of weekly docetaxel/gemcitabine followed by erlotinib on progression, vs the reverse sequence, in elderly patients with advanced non small-cell lung cancer selected with a comprehensive geriatric assessment (the gfpc 0504 study) |
topic | Clinical Study |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3208485/ https://www.ncbi.nlm.nih.gov/pubmed/21934690 http://dx.doi.org/10.1038/bjc.2011.331 |
work_keys_str_mv | AT lecaerh amulticentrephaseiirandomisedtrialofweeklydocetaxelgemcitabinefollowedbyerlotinibonprogressionvsthereversesequenceinelderlypatientswithadvancednonsmallcelllungcancerselectedwithacomprehensivegeriatricassessmentthegfpc0504study AT barlesif amulticentrephaseiirandomisedtrialofweeklydocetaxelgemcitabinefollowedbyerlotinibonprogressionvsthereversesequenceinelderlypatientswithadvancednonsmallcelllungcancerselectedwithacomprehensivegeriatricassessmentthegfpc0504study AT correr amulticentrephaseiirandomisedtrialofweeklydocetaxelgemcitabinefollowedbyerlotinibonprogressionvsthereversesequenceinelderlypatientswithadvancednonsmallcelllungcancerselectedwithacomprehensivegeriatricassessmentthegfpc0504study AT jullianh amulticentrephaseiirandomisedtrialofweeklydocetaxelgemcitabinefollowedbyerlotinibonprogressionvsthereversesequenceinelderlypatientswithadvancednonsmallcelllungcancerselectedwithacomprehensivegeriatricassessmentthegfpc0504study AT botas amulticentrephaseiirandomisedtrialofweeklydocetaxelgemcitabinefollowedbyerlotinibonprogressionvsthereversesequenceinelderlypatientswithadvancednonsmallcelllungcancerselectedwithacomprehensivegeriatricassessmentthegfpc0504study AT falcherol amulticentrephaseiirandomisedtrialofweeklydocetaxelgemcitabinefollowedbyerlotinibonprogressionvsthereversesequenceinelderlypatientswithadvancednonsmallcelllungcancerselectedwithacomprehensivegeriatricassessmentthegfpc0504study AT vergnenegrea amulticentrephaseiirandomisedtrialofweeklydocetaxelgemcitabinefollowedbyerlotinibonprogressionvsthereversesequenceinelderlypatientswithadvancednonsmallcelllungcancerselectedwithacomprehensivegeriatricassessmentthegfpc0504study AT dujonc amulticentrephaseiirandomisedtrialofweeklydocetaxelgemcitabinefollowedbyerlotinibonprogressionvsthereversesequenceinelderlypatientswithadvancednonsmallcelllungcancerselectedwithacomprehensivegeriatricassessmentthegfpc0504study AT delhoumejy amulticentrephaseiirandomisedtrialofweeklydocetaxelgemcitabinefollowedbyerlotinibonprogressionvsthereversesequenceinelderlypatientswithadvancednonsmallcelllungcancerselectedwithacomprehensivegeriatricassessmentthegfpc0504study AT chouaidc amulticentrephaseiirandomisedtrialofweeklydocetaxelgemcitabinefollowedbyerlotinibonprogressionvsthereversesequenceinelderlypatientswithadvancednonsmallcelllungcancerselectedwithacomprehensivegeriatricassessmentthegfpc0504study AT amulticentrephaseiirandomisedtrialofweeklydocetaxelgemcitabinefollowedbyerlotinibonprogressionvsthereversesequenceinelderlypatientswithadvancednonsmallcelllungcancerselectedwithacomprehensivegeriatricassessmentthegfpc0504study AT lecaerh multicentrephaseiirandomisedtrialofweeklydocetaxelgemcitabinefollowedbyerlotinibonprogressionvsthereversesequenceinelderlypatientswithadvancednonsmallcelllungcancerselectedwithacomprehensivegeriatricassessmentthegfpc0504study AT barlesif multicentrephaseiirandomisedtrialofweeklydocetaxelgemcitabinefollowedbyerlotinibonprogressionvsthereversesequenceinelderlypatientswithadvancednonsmallcelllungcancerselectedwithacomprehensivegeriatricassessmentthegfpc0504study AT correr multicentrephaseiirandomisedtrialofweeklydocetaxelgemcitabinefollowedbyerlotinibonprogressionvsthereversesequenceinelderlypatientswithadvancednonsmallcelllungcancerselectedwithacomprehensivegeriatricassessmentthegfpc0504study AT jullianh multicentrephaseiirandomisedtrialofweeklydocetaxelgemcitabinefollowedbyerlotinibonprogressionvsthereversesequenceinelderlypatientswithadvancednonsmallcelllungcancerselectedwithacomprehensivegeriatricassessmentthegfpc0504study AT botas multicentrephaseiirandomisedtrialofweeklydocetaxelgemcitabinefollowedbyerlotinibonprogressionvsthereversesequenceinelderlypatientswithadvancednonsmallcelllungcancerselectedwithacomprehensivegeriatricassessmentthegfpc0504study AT falcherol multicentrephaseiirandomisedtrialofweeklydocetaxelgemcitabinefollowedbyerlotinibonprogressionvsthereversesequenceinelderlypatientswithadvancednonsmallcelllungcancerselectedwithacomprehensivegeriatricassessmentthegfpc0504study AT vergnenegrea multicentrephaseiirandomisedtrialofweeklydocetaxelgemcitabinefollowedbyerlotinibonprogressionvsthereversesequenceinelderlypatientswithadvancednonsmallcelllungcancerselectedwithacomprehensivegeriatricassessmentthegfpc0504study AT dujonc multicentrephaseiirandomisedtrialofweeklydocetaxelgemcitabinefollowedbyerlotinibonprogressionvsthereversesequenceinelderlypatientswithadvancednonsmallcelllungcancerselectedwithacomprehensivegeriatricassessmentthegfpc0504study AT delhoumejy multicentrephaseiirandomisedtrialofweeklydocetaxelgemcitabinefollowedbyerlotinibonprogressionvsthereversesequenceinelderlypatientswithadvancednonsmallcelllungcancerselectedwithacomprehensivegeriatricassessmentthegfpc0504study AT chouaidc multicentrephaseiirandomisedtrialofweeklydocetaxelgemcitabinefollowedbyerlotinibonprogressionvsthereversesequenceinelderlypatientswithadvancednonsmallcelllungcancerselectedwithacomprehensivegeriatricassessmentthegfpc0504study AT multicentrephaseiirandomisedtrialofweeklydocetaxelgemcitabinefollowedbyerlotinibonprogressionvsthereversesequenceinelderlypatientswithadvancednonsmallcelllungcancerselectedwithacomprehensivegeriatricassessmentthegfpc0504study |